The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.
 
Sebastien J. Hotte
Consulting or Advisory Role - Astellas Pharma; Janssen
 
Anthony M. Joshua
No Relationships to Disclose
 
Vamsee Torri
No Relationships to Disclose
 
Robyn Jane Macfarlane
No Relationships to Disclose
 
Naveen S. Basappa
No Relationships to Disclose
 
Jean Powers
No Relationships to Disclose
 
Eric Winquist
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Oncogenex (Inst); Oncolytics (Inst); Oncothyreon (Inst); Roche (Inst); Sanofi (Inst)
 
Som Mukherjee
No Relationships to Disclose
 
Richard William Gregg
No Relationships to Disclose
 
Christian K. Kollmannsberger
No Relationships to Disclose
 
Daygen L. Finch
No Relationships to Disclose
 
Hao Xu
No Relationships to Disclose
 
Diana Felice Hausman
Employment - Oncothyreon
Stock and Other Ownership Interests - Oncothyreon
 
Lesley Seymour
Stock and Other Ownership Interests - AstraZeneca
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst)
 
Elizabeth A. Eisenhauer
No Relationships to Disclose
 
Kim N. Chi
No Relationships to Disclose